We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia (SWN-K)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00749970
First Posted: September 10, 2008
Last Update Posted: December 10, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
September 9, 2008
September 10, 2008
December 10, 2010
July 2008
January 2009   (Final data collection date for primary outcome measure)
  • SWN-K [ Time Frame: 7 days ]
  • PANSS [ Time Frame: 7 days ]
Same as current
Complete list of historical versions of study NCT00749970 on ClinicalTrials.gov Archive Site
CGI-I [ Time Frame: 7 days ]
Same as current
Not Provided
Not Provided
 
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patient aged 18-year old or older with a diagnosis of schizophrenia, schizoaffective disorder, or shizophreniform disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
January 2009
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder (DSM-IV TR criteria)
  • Stabilized out-patients
  • Under treatment with an oral antipsychotic drug

Exclusion Criteria:

  • Administration of a depot antipsychotic drug
  • Participation in another clinical trial within 4 weeks prior to enrolment into this study
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00749970
NIS-NES-DUM-2008/1
No
Not Provided
Not Provided
Teresa Diez, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Not Provided
AstraZeneca
December 2010